Original Article | Published:

Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model

Molecular Psychiatry volume 22, pages 14921501 (2017) | Download Citation

Abstract

An increasing literature suggests that schizophrenia is associated with a reduction in hippocampal interneuron function. Thus, we posit that stem cell-derived interneuron transplants may be an effective therapeutic strategy to reduce hippocampal hyperactivity and attenuate behavioral deficits in schizophrenia. Here we used a dual-reporter embryonic stem cell line to generate enriched populations of parvalbumin (PV)- or somatostatin (SST)-positive interneurons, which were transplanted into the ventral hippocampus of the methylazoxymethanol rodent model of schizophrenia. These interneuron transplants integrate within the existing circuitry, reduce hippocampal hyperactivity and normalize aberrant dopamine neuron activity. Further, interneuron transplants alleviate behaviors that model negative and cognitive symptoms, including deficits in social interaction and cognitive inflexibility. Interestingly, PV- and SST-enriched transplants produced differential effects on behavior, with PV-enriched populations effectively normalizing all the behaviors examined. These data suggest that the stem cell-derived interneuron transplants may represent a novel therapeutic strategy for schizophrenia.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , . Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 1975; 72: 4376–4380.

  2. 2.

    , , , , , et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–962.

  3. 3.

    , , , , , et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 2015; 165: 76–82.

  4. 4.

    . Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Pychiatry 2014; 75(Suppl 1): 21–26.

  5. 5.

    , . Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci 2011; 32: 507–513.

  6. 6.

    , . Injections of N-methyl-D-aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Synapse 1999; 31: 241–249.

  7. 7.

    , . Hippocampal efferents reach widespread areas of cerebral cortex and amygdala in the rhesus monkey. Science 1977; 198: 315–317.

  8. 8.

    , . Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 2000; 20: 4320–4324.

  9. 9.

    , , , , , et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011; 477: 171–178.

  10. 10.

    , , , , , et al. SPECT study of visual fixation in schizophrenia and comparison subjects. Biol Psychiatry 1999; 46: 89–93.

  11. 11.

    , , , , , et al. DIfferential targeting of the ca1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 2009; 66: 938–946.

  12. 12.

    , . GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res 2014; 167: 4–11.

  13. 13.

    , , . Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312–324.

  14. 14.

    , . A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002; 55: 1–10.

  15. 15.

    , , , , , et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res 2011; 131: 165–173.

  16. 16.

    , , . A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophr Res 2014; 157: 238–243.

  17. 17.

    , . Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia. Mol Psychiatry 2013; 18: 1193–1198.

  18. 18.

    , . The origin and specification of cortical interneurons. Nat Rev Neurosci 2006; 7: 687–696.

  19. 19.

    , , , , . In utero fate mapping reveals distinct migratory pathways and fates of neurons born in the mammalian basal forebrain. Development 2001; 128: 3759–3771.

  20. 20.

    , , , , , et al. Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal disinhibition. Proc Natl Acad Sci 2014; 111: 7450–7455.

  21. 21.

    , , , , , . Duration of culture and sonic hedgehog signaling differentially specify PV versus SST cortical interneuron fates from embryonic stem cells. Development 2015; 142: 1267–1278.

  22. 22.

    , . Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 2009; 204: 306–312.

  23. 23.

    . Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. I. Behavioral correlates and firing repertoires. Exp Neurol 1973; 41: 461–531.

  24. 24.

    , . Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—1. Identification and characterization. Neuroscience 1983; 10: 301–315.

  25. 25.

    , , . Modulatory effects of norepinephrine, acting on alpha1 receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress. Neuropharmacology 2002; 43: 1139–1147.

  26. 26.

    , . Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 2006; 137: 1039–1049.

  27. 27.

    , . Aberrant Hippocampal Activity Underlies the Dopamine Dysregulation in an Animal Model of Schizophrenia. J Neurosci 2007; 27: 11424–11430.

  28. 28.

    , . The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 2006; 31: 1356–1361.

  29. 29.

    , , . Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 2001; 21: 4915–4922.

  30. 30.

    , , , , , . Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 1999; 37: 251–270.

  31. 31.

    , , , , , . Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator. Neuropsychopharmacology 2012; 37: 1057–1066.

  32. 32.

    , , , , , . A spatial bias for the origins of interneuron subgroups within the medial ganglionic eminence. Dev Biol 2008; 314: 127–136.

  33. 33.

    , , . Spatial and temporal bias in the mitotic origins of somatostatin- and parvalbumin-expressing interneuron subgroups and the chandelier subtype in the medial ganglionic eminence. Cereb Cortex 2012; 22: 820–827.

  34. 34.

    , , . Sonic hedgehog maintains the identity of cortical interneuron progenitors in the ventral telencephalon. Development 2005; 132: 4987–4998.

  35. 35.

    , , , , , . Sonic hedgehog signaling confers ventral telencephalic progenitors with distinct cortical interneuron fates. Neuron 2010; 65: 328–340.

  36. 36.

    , . Fate determination of cerebral cortical GABAergic interneurons and their derivation from stem cells. Brain Res (in press).

  37. 37.

    , . The protracted maturation of human ESC-derived interneurons. Cell Cycle 2013; 12: 3129–3130.

  38. 38.

    , , , , , . Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 2004; 5: 793–807.

  39. 39.

    . Physiological subgroups of nonpyramidal cells with specific morphological characteristics in layer II/III of rat frontal cortex. J Neurosci 1995; 15: 2638–2655.

  40. 40.

    , . Physiological and morphological identification of somatostatin- or vasoactive intestinal polypeptide-containing cells among GABAergic cell subtypes in rat frontal cortex. TJ Neurosci 1996; 16: 2701–2715.

  41. 41.

    , , , . Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474–1486.

  42. 42.

    , , . Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol 2010; 20: 199–204.

  43. 43.

    , , . Dissociation in prefrontal cortex of affective and attentional shifts. Nature 1996; 380: 69–72.

  44. 44.

    , , , , , . Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. J Neurosci 2009; 29: 1538–1543.

  45. 45.

    , , , , , . Dopamine DRD2 polymorphism alters reversal learning and associated neural activity. J Neurosci 2009; 29: 3695–3704.

  46. 46.

    , , , , . Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb Cortex 2007; 17: 18–27.

  47. 47.

    , , , . Dopamine, but not serotonin, regulates reversal learning in the marmoset caudate nucleus. J Neurosci 2011; 31: 4290–4297.

  48. 48.

    , , . Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior. Psychopharmacology 2009; 202: 611–620.

  49. 49.

    , , , . Dopamine D2/D3 receptors play a specific role in the reversal of a learned visual discrimination in monkeys. Neuropsychopharmacology 2007; 32: 2125–2134.

  50. 50.

    , . Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Rev 2000; 31: 138–146.

  51. 51.

    , , , . Stability of set-shifting and planning abilities in patients with schizophrenia. Psychiatry Res 2004; 129: 229–239.

  52. 52.

    , , , , , et al. Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: Stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 2009; 66: 586–593.

  53. 53.

    , . Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus vulgaris-leucoagglutinin. J Comp Neurol 1991; 313: 574–586.

  54. 54.

    , , . Preputial separation as an external sign of pubertal development in the male rat. Biol Reprod 1977; 17: 298–303.

  55. 55.

    , , . An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia. Dev Neurobiol 2014; 74: 907–917.

  56. 56.

    , , , . Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785–1804.

  57. 57.

    , , , , , et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14: 507–509.

  58. 58.

    , . Moving stem cells to the clinic: potential and limitations for brain repair. Neuron 2015; 86: 187–206.

Download references

Acknowledgements

This work was supported by the Owens Foundation and by R01 MH090067 (DL) and R01 MH066912 (SA), and R01 DA032701 (MB) from the NIH. Cell sorting was performed by the Flow Cytometry Shared Resource Facility, supported by UTHSCSA, NIH-NCI P30 CA054174-20 (CTRC at UTHSCSA) and UL1 TR001120 (CTSA grant). We would like to acknowledge Jordan Thomas for his technical assistance.

Author contributions

JJD and DJL participated in research design. JJD and SYB conducted experiments. JAT and SAA contributed new reagents. JJD, SYB, MJB and DJL performed the data analysis. All authors wrote or contributed to the writing of the manuscript.

Author information

Affiliations

  1. Department of Pharmacology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX, USA

    • J J Donegan
    •  & D J Lodge
  2. Department of Psychiatry, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    • J A Tyson
    •  & S A Anderson
  3. Department of Physiology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX, USA

    • S Y Branch
    •  & M J Beckstead

Authors

  1. Search for J J Donegan in:

  2. Search for J A Tyson in:

  3. Search for S Y Branch in:

  4. Search for M J Beckstead in:

  5. Search for S A Anderson in:

  6. Search for D J Lodge in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to J J Donegan.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/mp.2016.121

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)

Further reading